Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
PHASE3
A randomized multi-arm study evaluating the efficacy and safety of nivoluma...
Estrogen and Cooperation, Competitiveness, and Risk Preferences
N/A
This study observes the effects of female cycle hormones on cooperation, co...
Status
Unknown
Location
RWTH Aachen University Hospital
Start Date
2018-10-08
Trial ID
NCT03584971
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
PHASE3
This protocol is designed to compare the effect on bone of Zoledronic Acid ...